Monitor for any court rulings on preliminary injunctions that could delay or impose conditions on the tender offer closing by November 16. The volume of demand letters (15) suggests a coordinated plaintiff effort, but the board's stated intention to vigorously defend indicates no settlement is imminent.
PCRX drugs
PCRX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 13 $36.46entry
- T+1 · 19h ago +0.05%α +1.97% · $36.48
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outExecutive Summary
Pacira BioSciences filed Amendment No. 2 to its Schedule 14D-9, updating the legal proceedings section to disclose that two stockholder lawsuits and fifteen demand letters have been filed challenging the adequacy of disclosures in the merger with Viatris. The board continues to recommend the $36.50 per share tender offer, and the Pacira defendants intend to vigorously defend the actions.
Key Facts
- Two stockholder complaints filed in New York state court alleging omitted or misrepresented material information in the Schedule 14D-9 regarding the merger
- Fifteen demand letters received, including two draft complaints, seeking additional disclosure
- Pacira defendants have not been served with the complaints
- Board continues to recommend the $36.50 per share cash tender offer by Viatris
- Tender offer expires November 16, 2026
Financial Impact
No financial impact stated; litigation seeks injunctive relief and damages if merger consummated, but outcome is uncertain
Risk Factors
- Preliminary injunction could delay merger closing
- Additional damages if merger consummated and plaintiffs prevail
- Further complaints or demand letters may be filed
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 14D-9/A Filing (Primary) | 0001140361-26-043433 |
| Document: 0001140361-26-043433-index-headers.html | 0001140361-26-043433 |
| Document: 0001140361-26-043433-index.html | 0001140361-26-043433 |
| Document: 0001140361-26-043433.txt | 0001140361-26-043433 |
Track record
29 reports on PCRX
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
- Nov 12, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 12, 20264d ago SC 14D-9/A Neutral 3/10 Viewing Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
- Nov 3, 202613d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC 14D-9 Bullish 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC TO-T Mixed 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 13, 20264w ago SC 13D/A Bearish 7/10 Entry $36.40 to $36.46 Now $36.48 −0.22% ▼ −0.16% −1.44% vs SPY
- Oct 8, 20265w ago SC TO-C Bullish 7/10 Entry $36.31 to $36.43 Now $36.48 +0.47% ▲ +0.33% +5.89% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers